Skip to content

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer - Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014671
Enrollment
20
Registered
2014-07-28
Start date
2014-07-29
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

Sponsors

Radiation Oncology, Tokai University Hachioji Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1)Patients who have had any other cancer within the past 5 years 2)Patients who have uncontrollable diabetes mellitus 3)Patients who have serious comorbidities such as collagen disease, heart disease, interstitial pneumonia, liver cirrhosis 4)patients who have a psychological problem 5)patients who had previously received pelvic irradiation 6)patients who had previously received pelvic surgery 7)patients who had previously received TURP, orchiectomy, or HIFU 8)patients who had previously received chemotherapy for prostate cancer 9)patients who have Crohn's disease or ulcerative colitis 10)patients who require concomitant anticoagulant therapy 11)IPSS at registration>=20

Design outcomes

Primary

MeasureTime frame
the incidence of delayed adverse events at 5 years

Countries

Japan

Contacts

Public ContactAkitomo Sugawara

Tokai University Hachioji Hospital Radiation Oncology

h4411@wave.plala.or.jp042-639-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026